Neuroanesthesia & neurocritical care
Clinical features and factors associated with outcomes of antibody-negative autoimmune encephalitis in patients requiring intensive care
Authors' conclusion
While high-dose corticosteroids are frequently used to treat AE, their risks may outweigh their benefits in severe antibody-negative AE cases.
Study context
- Population
- Adults with antibody-negative autoimmune encephalitis admitted to the intensive care unit (ICU) of a large tertiary hospital, 2019–2023of 1220 severe encephalitis ICU patients
- Participants
- 107 adults
- Outcome
- Poor functional outcome (modified Rankin Scale score 3-6)
- Follow-up
- Six months after ICU admission
Methodological detailssingle-centre, consecutive patients
- Single-centre
- Consecutive patients
Main finding
As reported in the abstract
Poor functional outcome and factors independently associated
Odds ratio (95% CI)
High-dose corticosteroid therapy
8.734(2.483–30.717)
Older age at onset
1.063(1.028–1.099)
Acute respiratory failure at ICU admission
10.931(2.062–57.751)
Dyskinesia/dystonia
14.109(1.336–148.957)
- Poor functional outcome
- 67 (62.6%)
- Deaths
- 28 (26.2%)
Observational data: associations, not effects.
Further findings
Longitudinal Clinical Assessment Scale in Autoimmune Encephalitis and modified Rankin Scale scores (generalized linear mixed model)
- High-dose corticosteroid therapy associated with poorer longitudinal outcomes
Original publication
Clinical features and factors associated with outcomes of antibody-negative autoimmune encephalitis in patients requiring intensive care. Crit Care. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →